Jérôme Deval

904 total citations
13 papers, 402 citations indexed

About

Jérôme Deval is a scholar working on Infectious Diseases, Molecular Biology and Hepatology. According to data from OpenAlex, Jérôme Deval has authored 13 papers receiving a total of 402 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Infectious Diseases, 6 papers in Molecular Biology and 6 papers in Hepatology. Recurrent topics in Jérôme Deval's work include Hepatitis C virus research (6 papers), Biochemical and Molecular Research (5 papers) and HIV/AIDS drug development and treatment (5 papers). Jérôme Deval is often cited by papers focused on Hepatitis C virus research (6 papers), Biochemical and Molecular Research (5 papers) and HIV/AIDS drug development and treatment (5 papers). Jérôme Deval collaborates with scholars based in United States, France and Belgium. Jérôme Deval's co-authors include Julian Symons, Shuvam Chaudhuri, Bruno Canard, Tania Ivens, Herwig Van Marck, Maryam Ehteshami, Marcia Van Ginderen, Pascale Dehertogh, Matthias Götte and Piet Wigerinck and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Virology and Journal of Hepatology.

In The Last Decade

Jérôme Deval

13 papers receiving 390 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jérôme Deval United States	8	237	146	118	114	45	13	402
M. Henes United States	11	138 0.6×	102 0.7×	48 0.4×	84 0.7×	44 1.0×	16	268
Kristina Prachanronarong United States	9	150 0.6×	126 0.9×	106 0.9×	71 0.6×	31 0.7×	11	329
Florian Leidner United States	11	144 0.6×	116 0.8×	46 0.4×	96 0.8×	40 0.9×	16	260
Adele Boccuto Italy	15	236 1.0×	88 0.6×	71 0.6×	98 0.9×	23 0.5×	30	439
Brenda I. Hernández-Santiago United States	9	307 1.3×	143 1.0×	167 1.4×	114 1.0×	15 0.3×	16	451
Ona Barauskas United States	9	244 1.0×	142 1.0×	183 1.6×	58 0.5×	37 0.8×	15	513
Peggy Geluykens Belgium	7	241 1.0×	126 0.9×	91 0.8×	194 1.7×	40 0.9×	10	345
Colin Anthony South Africa	10	161 0.7×	196 1.3×	52 0.4×	300 2.6×	47 1.0×	10	501
Djadé I. Soumana United States	8	200 0.8×	137 0.9×	150 1.3×	36 0.3×	61 1.4×	8	441
Carrie A. Rutkowski United States	11	295 1.2×	196 1.3×	138 1.2×	113 1.0×	27 0.6×	13	518

Countries citing papers authored by Jérôme Deval

Since Specialization

Citations

This map shows the geographic impact of Jérôme Deval's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jérôme Deval with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jérôme Deval more than expected).

Fields of papers citing papers by Jérôme Deval

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jérôme Deval. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jérôme Deval. The network helps show where Jérôme Deval may publish in the future.

Co-authorship network of co-authors of Jérôme Deval

This figure shows the co-authorship network connecting the top 25 collaborators of Jérôme Deval. A scholar is included among the top collaborators of Jérôme Deval based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jérôme Deval. Jérôme Deval is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

Wu, Tongfei, Sarah Stevens, Cheng Liu, et al.. (2022). Discovery of oral PDL1 small molecule inhibitors specifically designed for the treatment of chronic hepatitis B. Journal of Hepatology. 77. S853–S853. 2 indexed citations

Liu, Cheng, Sandro Boland, Michael D. Scholle, et al.. (2021). Dual inhibition of SARS-CoV-2 and human rhinovirus with protease inhibitors in clinical development. Antiviral Research. 187. 105020–105020. 39 indexed citations

Zhang, Qingling, Sandrine Vendeville, V. N. Serebryany, et al.. (2020). ALG-000184, a prodrug of capsid assembly modulator ALG-001075, demonstrates best-in-class preclinical characteristics for the treatment of chronic hepatitis B. Journal of Hepatology. 73. S880–S881. 4 indexed citations

Chaudhuri, Shuvam, Julian Symons, & Jérôme Deval. (2018). Innovation and trends in the development and approval of antiviral medicines: 1987–2017 and beyond. Antiviral Research. 155. 76–88. 142 indexed citations

Jin, Zhinan, April Kinkade, Shuvam Chaudhuri, et al.. (2017). Structure-activity relationship analysis of mitochondrial toxicity caused by antiviral ribonucleoside analogs. Antiviral Research. 143. 151–161. 38 indexed citations

Jordan, Paul C., Sarah Stevens, Yuen Yi C. Tam, et al.. (2016). Activation Pathway of a Nucleoside Analog Inhibiting Respiratory Syncytial Virus Polymerase. ACS Chemical Biology. 12(1). 83–91. 14 indexed citations

Tan, Hua, Kenneth J. Shaw, Jérôme Deval, et al.. (2015). P0682 : Preclinical characterization of AL-335, a potent uridine based nucleoside polymerase inhibitor for the treatment of chronic hepatitis C. Journal of Hepatology. 62. S577–S578. 3 indexed citations

Tan, Hongyu, Jérôme Deval, Jin Zhang, et al.. (2013). 1219 VX-135, A POTENT SINGLE DIASTEREOMER OF ALS-2200, FOR THE TREATMENT OF CHRONIC HEPATITIS C. Journal of Hepatology. 58. S495–S495. 2 indexed citations

Kutach, Alan K., Armando G. Villaseñor, Charles Belunis, et al.. (2010). Crystal Structures of IL‐2‐inducible T cell Kinase Complexed with Inhibitors: Insights into Rational Drug Design and Activity Regulation. Chemical Biology & Drug Design. 76(2). 154–163. 33 indexed citations

10.

Bussetta, Cécile, et al.. (2008). Gln151 of HIV-1 Reverse Transcriptase Acts as a Steric Gate Towards Clinically Relevant Acyclic Phosphonate Nucleotide Analogues. Antiviral Therapy. 13(1). 115–124. 10 indexed citations

11.

Jochmans, Dirk, Jérôme Deval, Bart Kesteleyn, et al.. (2006). Indolopyridones Inhibit Human Immunodeficiency Virus Reverse Transcriptase with a Novel Mechanism of Action. Journal of Virology. 80(24). 12283–12292. 77 indexed citations

12.

Menéndez‐Arias, Luis, Tania Matamoros, Jérôme Deval, & Bruno Canard. (2005). Molecular Mechanisms of Resistance to Nucleoside Analogue Inhibitors of Human Immunodeficiency Virus Reverse Transcriptase. 2(2). 101–113. 5 indexed citations

13.

Deval, Jérôme, Karine Alvarez, Boulbaba Selmi, et al.. (2004). Mechanistic Insights into the Suppression of Drug Resistance by Human Immunodeficiency Virus Type 1 Reverse Transcriptase Using α-Boranophosphate Nucleoside Analogs. Journal of Biological Chemistry. 280(5). 3838–3846. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact